Related Experiment Video

Updated: Aug 6, 2026

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

19.1K

Case Series: Cancer-Related Facial Pain Treated with Stellate Ganglion Block

Raheleh Rahimi Darabad1, Jerry P Kalangara2,3, Anna Woodbury2,3

  • 1Department of Anesthesiology and Pain Management, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Palliative Medicine Reports
|July 5, 2021
PubMed

Keywords:
cancerorofacial painstellate ganglion blocksympathetic ganglia

More Related Videos

Ethanol-Induced Cervical Sympathetic Ganglion Block Applications for Promoting Canine Inferior Alveolar Nerve Regeneration Using an Artificial Nerve06:48

Ethanol-Induced Cervical Sympathetic Ganglion Block Applications for Promoting Canine Inferior Alveolar Nerve Regeneration Using an Artificial Nerve

Published on: November 30, 2018

9.0K
Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration05:04

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration

Published on: May 5, 2020

7.7K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups: